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Abstract
Chronic kidney disease (CKD) is a highly prevalent condition in the world. Neurological, psychological, and cognitive disorders,
related to CKD, could contribute to the morbidity, mortality, and poor quality of life of these patients. The aim of this study was to
assess the neurological, psychological, and cognitive imbalance in patients with CKD on conservative and replacement therapy.
Seventy-four clinically stable patients affected by CKD on conservative therapy, replacement therapy (hemodialysis (HD),
peritoneal dialysis (PD)), or with kidney transplantation (KT) and 25 healthy controls (HC), matched for age and sex were enrolled.
Clinical, laboratory, and instrumental examinations, as renal function, inflammation and mineral metabolism indexes,
electroencephalogram (EEG), psychological (MMPI-2, Sat P), and cognitive tests (neuropsychological tests, NPZ5) were carried out.
The results showed a significant differences in the absolute and relative power of delta band and relative power of theta band of
EEG (P=0.008, P<0.001, P=0.051), a positive correlation between relative power of delta band and C-reactive protein (CRP) (P<
0.001) and a negative correlation between estimated glomerular filtration rate (eGFR) (P<0.001) and 1,25-dihydroxyvitamin D3
(1,25-(OH)2D3) (P<0.001), in all the samples. Qualitative analysis of EEG showed alterations of Grade 2 (according to
Parsons–Smith classification) in patients on conservative therapy, and Grade 2–3 in KT patients. The scales of MMPI-2 hysteria and
paranoia, are significantly correlated with creatinine, eGFR, serum nitrogen, CRP, 1,25-(OH)2D3, intact parathyroid hormone (iPTH),
phosphorus, and cynical and hysterical personality, are correlated with higher relative power of delta (P=0.016) and theta band (P=
0.016). Moreover, all NPZ5 scores showed a significant difference between the means of nephropathic patients and the means of the
HC, and a positive correlation with eGFR, serum nitrogen, CRP, iPTH, and vitamin D.
In CKD patients, simple and noninvasive instruments, as EEG, and cognitive-psychological tests, should be performed and careful
and constant monitoring of renal risk factors, probably involved in neuropsychological complications (inflammation, disorders of
mineral metabolism, electrolyte disorders, etc.), should be carried out. Early identification and adequate therapy of
neuropsychological, and cognitive disorders, might enable a better quality of life and a major compliance with a probable
reduction in the healthcare costs.
Abbreviations: 1,25-(OH)2D3 = 1,25-dihydroxyvitamin D3, BMI = body mass index, CARHES = Health Examination Survey
study, CKD = chronic kidney disease, CRP = C-reactive protein, Cyn = cynicism, DST = digit span test, EEG =
electroencephalogram, eGFR = estimated glomerular filtration rate, ESV = erythrocyte sedimentation velocity, GCs = guanidino
compounds, GPT = Grooved Pegboard Test, HC = healthy controls, HD = hemodialysis, HDL = high-density lipoprotein, Hy =
hysteria, iPTH = parathormone, KDOQI = Kidney Disease Outcomes Quality Initiative, KT = kidney transplantation, LDL = low-
density lipoprotein, MDRD =Modification of Diet in Renal Disease, MMPI-2 =Minnesota multiphasic personality inventory, NHANES
=National Health and Nutrition Examination Survey III, NPZ5= neuropsychological test, Pa= paranoia, PD= peritoneal dialysis, Pd=
psychopathic deviate, RAVL = Rey auditory verbal learning test, SAT-P = satisfaction profile, SDMT = symbol digit modalities test,
TMTT = trail-making test.
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Lai et al. Medicine (2016) 95:48 MedicineChronic kidney disease (CKD) is a highly prevalent condition and
infections), and 25 healthy controls (HC)matched for age and sex.1. Introduction
its prevalence is growing in the world. Epidemiological data
derived from cardiovascular risk in renal patients of the Health
Examination Survey study (CARHES)[1] showed a prevalence of
CKD in Italy of 7.5% for men and 6.5% for women, and the
National Health and Nutrition Examination Survey III
(NHANES III),[2] showed that CKD is estimated at about
10% of the world population. The CKD is a clinical condition
that can progress to the end-stage renal disease, with high
cardiovascular morbidity and mortality,[3] that is not fully
explained by traditional risk factors, but partially explained by
risk factors associated with CKD (mineral metabolism disorders,
metabolic acidosis, endothelial dysfunction, inflammation,
oxidative stress, etc.). Even the neurological complications
related to CKD, greatly contribute to the morbidity, mortality,
and poor quality of life of these patients. Neurological
complications are characterized by cognitive impairment,
anxiety, fatigue, apathy, clumsiness, irritability, sleep disturban-
ces, and impaired concentration. Moreover the patient may
become emotionally labile, more obviously forgetful and
sluggish, make perceptual errors, and develop sleep inversion
until sleep myoclonus. These patients may manifest, also,
peripheral neuropathy, leading to weakness and disability, but
currently these clinical manifestations are avoided by early
replacement therapy.[4,5] Cognitive decline is significantly
associated with CKD, regardless of age and other potential
confounding factors.[6] Elias and Elias[7] and Kurella Tamura and
Wadley[8] showed early appearance of global cognitive deficit in
CKD, which progressively increases with worsening renal
function, independently from other traditional risk factors.
Furthermore, another fundamental aspect that has been consid-
ered in recent years is related to psychological problems, that may
appear along with neurological and cognitive disorders and that
significantly reduce the quality of life of these patients.
2. Aim of the study
The aimof this studywas to assess the neurological, psychological,
and cognitive disorders in patients with CKD (Stage 4/5 Kidney
Disease Outcomes Quality Initiative (KDOQI)), in conservative
and replacement therapy ((hemodialysis (HD), peritoneal dialysis
(PD)), or with kidney transplantation (KT)) and the correlation
with risk factors associated with renal disease.3. Materials and methods
The study protocol was approved by the Clinical Research Ethics
Committee of University Hospital “Policlinico Umberto I” of
Rome, Sapienza University of Rome, Italy with protocol number
807/12. The study conforms to the principles outlined in the
Declaration of Helsinki and we obtained a written consent from
each patient before the enrollment.3.1. Study design and subjects
We performed an observational study on 99 clinically stable
patients, enrolled from December 2013 to March 2015, at the
University Hospital “Policlinico Umberto I” of Rome, Sapienza
University of Rome, Italy. The study included 22 patients with
CKD on conservative therapy (eGFR30mL/min, stage 4/5
KDOQI), 15 patients on HD, 16 patients on PD, 21 patients with
KT (from at least 36 months with eGFR ≥60mL/min, in the2absence of acute renal failure, without proteinuria or renal
Statins, antihypertensive, antiplatelet therapies, and/or therapies
with calcium, calcitriol, and phosphate binders were continued in
all patients included in the study. We excluded patients with heart
failure, liver insufficiency, chronic obstructive pulmonary disease,
cerebrovascular disease, degenerative neurological or psychiatric
diseases, acute myocardial infarction, and acute coronary
syndrome within 3 months before the study. Patients who refused
to give consent and patients with missing data were not enrolled.
eGFRwas calculated with the abbreviatedModification of Diet in
Renal Disease (MDRD) formula, as defined by Levey et al.[9]
Clinical, laboratory, and instrumental examinations, and neuro-
psychological tests were carried out. Clinical and instrumental
examinations ofHDpatients were performed during themiddle of
the week, after HD treatment, while PD patients were examined
before the first replacement of the morning with an empty
peritoneum at routine visits.[10]
3.2. Anthropometric assessments
Body weight was determined to the nearest 0.1kg using a
calibrated digital scale. Body mass index (BMI) was calculated by
the formula: [weight (kg)/height (m2)].
3.3. Laboratory measurements
Bloodwas drawn in the morning after an overnight fast of at least
12hours. In all patients, the levels of fasting plasma glucose (mg/
dL), total serum cholesterol (mg/dL), triglycerides (mg/dL), high-
density lipoprotein (HDL) (mg/dL), serum creatinine (mg/dL),
hemoglobin (g/dL), nitrogen (mg/dL), serum uric acid (mg/dL),
serum calcium (mg/dL), phosphate (mg/dL), serum electrolytes
(mEq/L), C-reactive protein (CRP) (mg/L), and erythrocyte
sedimentation velocity (ESV) (mm/H) were measured using
standard automated techniques. Serum albumin (g/dL) was
determined by bromocresol purple method. Parathormone (pg/
mL) was measured using a 2-site assay that measures “intact”
hormone (iPTH). 1,25-Dihydroxyvitamin D3 (1,25-(OH)2D3)
(ng/mL) was measured by radioimmunoassay. Low-density
lipoprotein (LDL)-cholesterol (mg/dL) was calculated using the
Friedewald equation: LDL= total cholesterolHDL (triglyc-
erides/5). We have evaluated routine and microscopy urinalysis
and albuminuria in 24-hour urine in KT patients and calculated
urea-based dialysis adequacy Kt/V (K, dialyzer clearance of urea,
t, dialysis time, V, volume of distribution of urea), in particular
weekly standard Kt/V (sdtKt/V) in dialysis patients.[11,12] We
have also assessed plasma ammonia, hemogasanalysis, and
plasma concentration of immunosuppressive drugs to exclude
other forms of metabolic encephalopathy or brain damage
related to drug toxicity according to standard outpatient
protocols. Plasma ammonia was performed using venous blood
samples with ethylene diamine tetraacetic acid and to maintain
the cold chain, samples were quickly delivered to the laboratory
on ice. Plasma ammonia was measured by an enzymatic method
using glutamate dehydrogenase (Ammonia NH3L Cobas, Roche
Diagnostics, Inc., Tokyo, Japan). Hemogasanalysis was per-
formed using a blood gas analyzer (Nova Phox Plus C, Bollate
(MI), Italy).
3.4. Blood pressure measurements
Clinic blood pressure measurements were made three times after
10minutes of rest in a seated position using a standard automatic
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the British Hypertension Society guidelines and the mean values
for systolic blood pressure and diastolic blood pressure were
calculated for all participants.[13] Systolic and diastolic blood
pressure levels were measured at the routine visits with empty
abdomen, in patients on PD and in HD patients before and after
dialysis session.[10,14] The systolic and diastolic BP levels were
taken as the points of appearance and disappearance of
Korotkoff sounds, respectively. Hypertension was defined by
elevated SBP (>140mm Hg), DBP (>90mm Hg).3.5. Electroencephalogram (EEG)
Electroencephalogram (EEG) recordings were performed by a
digital apparatus (Micromed, Treviso, Italy) and sampled at a
rate of 256/second. According to the International 10-20
System,[15] the following scalp electrodes were applied: Fp2,
Fp1, F8, F7, F4, F3, C4, C3, T4, T3, P4, P3, O2, andO1. Baseline
EEG tracings were recorded for 20minutes, with eyes closed.
Tracings of patients and control subjects were blindly inspected
offline by 2 neurophysiologists who assessed the general
organization of the EEG background activity and the prevalence
and type of abnormalities. The severity of EEG changes was
classified according to a modification of the Parson–Smith
qualitative classification as: Grade 1 (normal EEG), Grade 2
(distinctive features of encephalopathy), and Grade 3 (signs of
severe encephalopathy).[16] For the quantitative analysis, 20
artifact-free epochs each lasting 4seconds, were randomly
selected from each baseline recording. According to a procedure
described elsewhere[16,17] on these tracing epochs and from the
mean values of all electrodes, the absolute (microV2) and relative
(%) power in the various frequency bands (delta=1–3.5Hz,
theta=4–7.5Hz, alpha=8–12.5Hz, beta1=13–19.5Hz, and
beta2=20–29Hz) were calculated.[18] Main dominant frequen-
cy and median frequency were also calculated.3.6. Neurological, psychological, and cognitive tests
All individuals completed a standardized battery of neuropsy-
chological tests:
3.6.1. Minnesota multiphasic personality inventory (MMPI-
2). The Minnesota multiphasic personality inventory-2 (MMPI-
2): a standardized psychometric test of adult personality and
psychopathology. MMPI-2 consists of 567 items. MMPI-2
includes 8 validity, 10 clinical, 16 additional, and 15 content
scales and each scale has several subscales (31 total). MMPI-2
operates with a value of ≥65 indicating an elevated score. This
cut-off score indicates distinct psychological problems or
pathology. MMPI-2 has been translated into Italian and it has
been thoroughly tested and adapted.[19]
3.6.2. Satisfaction profile (SAT-P). It is a test that provides both
qualitative and quantitative self-satisfaction assessment within
the health-related quality of life; the SAT-P is a self-report scale
widely used in the healthcare context. The scale defines
satisfaction as the result of a cognitive process that compares
real with ideal expectations. Level of satisfaction is linked to the
gap between real and ideal expectations. The SAT-P assesses
subjective satisfaction in the preceding month using 5 macro-
categories: Factor I (psychological functioning), Factor II
(physical functioning), Factor III (work), Factor IV (sleep/diet/
free time), and Factor V (social functioning). The questionnaire3consists of 32 items, measured on a visual analog scale: the level
of agreement with a statement is indicated by marking a position
along a continuous line (10cm) between 2 end-points (totally
satisfied/totally dissatisfied).[20] The score range is 0 to 100, 0=
total dissatisfaction and 100 complete satisfaction.
3.6.3. Neuropsychological test (NPZ5).Neurocognitive testing
was administered by a designated investigator at each study site
who had completed standardized training to administer the test
procedures. Five domains were assessed as follows:
Rey auditory verbal learning test (RAVL) (List A and List B)
evaluates different functions: short-term auditory-verbal memo-
ry, rate of learning, learning strategies, retroactive and proactive
interference, presence of confabulation of confusion in memory
processes, retention of information, and differences between
learning and retrieval.
Trail-making test (TMT) (Parts A and B) is a neurocognitive
test of visual attention and change task used in clinical settings for
the evaluation of cognitive deficits.
Digit span test (DST) (forward and backward) is used to
measure working memory’s number storage capacity.
Symbol digit modalities test (SDMT) (90 and 120seconds) is
widely used because it is easy to administer, reliable, and
evaluates information processing speed, including attention and
visual scanning.
Grooved Pegboard Test (GPT) (with dominant hand and with
nondominant hand) is a manipulative dexterity test and it
requires complete visual and motor coordination.[21]3.7. Statistical analysis
Data management and analysis were performed using IBM SPSS
Statistics 17 forWindows software and a probability value of P<
0.05 was considered to be statistically significant. All continuous
variables that follow a normal distribution were expressed as
mean (±standard deviation), and not normal variables were
expressed as median (IQR). Categorical variables were expressed
as number (percentage). Student t test or the Mann–Whitney U
test (two-tailed) or ANOVA were performed to determine the
differences between groups. The Chi-square test was used to
compare categorical variables. The Spearman or Pearson
correlation was used to determine the correlation bivariate
relationship and the strength of association between variables.
The groups were compared using Chi-square test, Kruskal–-
Wallis test, or analysis of variance. Variance inflation factor (VIF)
was used to quantified the severity of multicollinearity in an
ordinary least squares regression analysis. No problem of
multicollinearity was identified.4. Results
Table 1 shows the patient’s characteristics. In summary, there
were no significant differences between the groups, except for
values of creatinine (mg/dL) (P<0.001), MDRD (mL/min) (P<
0.001), serum nitrogen (mg/dL) (P<0.001), uric acid (mg/dL)
(P<0.001), potassium (mEq/L) (P<0.001), phosphorus (mEq/
L) (P<0.001), hemoglobin (g/L) (P<0.001), CRP (mg/L) (P<
0.001), ESV (mm/H) (P<0.001), iPTH (pg/mL) (P<0.001),
1,25-(OH)2D3(ng/mL) (P<0.001) (Table 1). The patients were
receiving adequate dose of dialysis, as measured by weekly
standard Kt/V (sdtKt/V), that was >2 in all dialysis patients.
The dosage of immunosuppressive therapy in patients with KT
was in the therapeutic range in all patients (data not shown).
Table 1
Patients’ characteristics.
CKD (n=22) HD (n=15) PD (n=16) KT (n=21) HC (n=25) P
Male, n (%) 12 (54.5) 6 (40) 10 (62.5) 8 (38.0) 8 (32.0) n.s.
Age, y 67±15.2 53±14.1 67±10.7 56.9±9.9 57.8±11.2 n.s.
BMI, kg/m2 23.8±2 23.5±3.4 23±2.4 23.5±1.6 23.2±2.5 n.s.
SBP, mm Hg 133.2±13 127.7±17.8 136.7±11 130.7±17.8 127.3±128 n.s.
DBP, mm Hg 79±9.8 76.3±7 82±9.7 77.9±11 77.5±6.6 n.s.
Serum creatinine, mg/dL 2.5±0.8 9.6±1.4 7.37±3.2 1.4±0.4 1±0.16 <0.001
MDRD, mL/min/1.72m2 25.5±9.1 5.2±1 8.2±3.8 49.4±17 72.3±15.3 <0.001
Serum nitrogen, mg/dL 92.9±29.6 156.7±31.9 135.6±36.5 57.0±29.0 37.7±4.9 <0.001
Serum uric acid, mg/dL 6.3±1.4 5.8±0.85 4.7±1.2 6.6±1.5 5.5±0.8 <0.001
Sodium, mEq/L 140.5±2.8 141.1±2.9 143.0±3.2 140.0±3.7 139.8±1.6 <0.001
Potassium, mEq/L 4.9±0.4 5.7±1.0 4.68±0.6 4.3±0.5 3.8±0.3 <0.001
Calcium, mg/dL 8.6±1.7 9.0±0.84 8.8±0.67 9.3±1.0 8.8±0.2 n.s.
Phosphorus, mg/dL 4±0.9 5.0±0.85 4.8±1.0 3.4±0.8 3.8±0.3 <0.001
Serum albumin, g/dL 4.9±0.6 4.2±0.29 3.9±0.4 3.8±0.4 4.3±0.5 n.s.
Serum glucose, mg/dL 105.8±28.6 90.2±17. 99.8±37.2 93.2±12 87.4±9.9 n.s.
Ammonium, mmol/L 42.8±8.5 48.6±5.3 46.0±5.8 44.0±6.8 44.9±5.9 n.s.
Hemoglobin, g/dL 12.0±1.4 11.27±1.37 12.0±1.0 13.0±1.4 13.9±0.7 <0.001
CRP, mg/L 10.4±10.3 12.75±7.9 15.4±5.4 3.3±2.8 2.0±1.6 <0.001
ESV, mm/h 42.7±28.4 44.7±30 70.3±28.3 44.7±20.5 17.8±8.6 <0.001
iPTH, pg/mL 174.2±78.4 247.8±232.4 330.7±175.7 126.5±67.3 53.0±9.8 <0.001
1,25-(OH)2D3, ng/mL 15.2±10.0 14.87±2.8 9.3±6.8 12.7±7.9 29.0±9.2 <0.001
Data are show as mean± standard deviation or number (%).
1,25-(OH)2D3=1,25-dihydroxyvitamin D3, BMI=body mass index, CKD=chronic kidney disease, CRP=C reactive protein, DBP=diastolic blood pressure, ESV=erythrocyte sedimentation velocity, HC=healthy
controls, HD=hemodialysis, iPTH= intact parathyroid hormone, KT= kidney transplant, MDRD=Modification of Diet in Renal Disease, n.s.=not significant, PD=peritoneal dialysis, SBP= systolic blood pressure.
Bold highlights the statistically significant values and italics the non-significant results.
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The quantitative analysis of EEG data, showed a significant
difference, between CKD patients and HC, of the relative and
absolute power of delta band (P<0.001, P=0.008) (Table 2),
more evident in PD patients (Fig. 1), of the relative power of theta
band (P=0.051), more evident in HD patients (P=0.019) and of
the relative and absolute power of Beta1 band (P=0.012, P=
0.022) (Table 2). The qualitative analysis of EEG data, showed
more regular and stable EEG, on conservative therapy and KT
patients, (most represented Grade 1 scale Parsons–Smith) (Fig. 2),
respect to HD and PD patients (greater Grade 2 and 3 scale
Parsons–Smith). However, also in conservative therapy patients,
EEG showed a lower percentage of Grade 2 and even Grade 3 on
KT patients, respect to HC (Fig. 2). Bivariate analysis showed a
negative correlation between relative power of delta band and
1,25-(OH)2D3 (Fig. 3), MDRD value (Fig. 4), and the TMT of
NPZ5 score (r=0.235, P=0.043), and a positive correlation with
CRP value (Fig. 5) and ESV (r=0.418, P<0.001) in all the
samples.Table 2
Quantitative analysis of EEG data.
CKD (n=22) HD (n=15) PD (
Abs (Delta) 12±3.7 19.8±18.7 20.4
Abs (Theta) 8.7±14.4 9.1±6.9 8.2
Abs (Alpha) 23.1±22.2 21.9±8 26.2
Abs (Beta1) 7.2±4.8 8.8±8 7.9
Rel (Delta) 29.4±13.3 36.8±14.2 51.5
Rel (Theta) 13.5±8.9 16.3±4.4 12.3
Rel (Alpha) 41.8±14.4 31.7±14.9 30.6
Rel (Beta1) 15±5.4 15.1±7.4 13.2
Abs (microV2) and Rel (%) power in the frequency bands.
Abs= absolute, CKD= chronic kidney disease, HC=healthy controls, HD=hemodialysis, KT= kidney tr
Bold highlights the statistically significant values and italics the non-significant results.
4EEG and MMPI-2 data analysis have showed that higher
relative power of delta band, positively correlates with the
content scale, Cyn (cynicism) (r=0.276, P=0.016) (Table 3), and
an increased relative power of theta band, positively correlated
with Hy (hysteria) (r=0.277, P=0.016), SC2 (emotional
alienation) (r=0.302, P=0.008), SC4 (depressive tendency
and apathy) (r=0.226, P=0.051), Fam (family problems) (r=
0.248, P=0.032), D (depression) (r=0.239, P=0.039), and Gf
(gender female; the perception of sexual role; r=0.346, P=
0.035), while negatively correlated with Gm (gender male; r=
0.244, P=0.002) (Table 3).4.2. MMPI-2, SAT-P, and NPZ5 test analysis
Analysis of variance of MMPI-2, showed a difference between
CKD patients and HC, in all baseline clinical scale D (depression)
(Fig. 6), in particular, the HD and PD groups showed a significant
difference of averages when compared with HC (P<0.001, P<
0.001) (Fig. 6). The scale Hy of MMPI-2 showed a positiven=16) KT (n=21) HC (n=25) P
±8.5 14.9±6.3 12.5±4.1 0.008
±6 5.4±4.9 12±12.1 0.297
±15.8 25.5±34.8 48.8±56.1 0.060
±4.3 6.7±3.3 11.9±5.8 0.012
±12.3 37.2±13.6 23.9±14.3 0.001
±4.7 10.5±3 12.7±4.6 0.051
±15.8 36.2±19 42.2±22.3 0.146
±6 15.9±6.5 20.9±11.3 0.022
ansplant, PD=peritoneal dialysis, Rel= relative.
Figure 1. Bar charts with error bars. The mean value of relative power of delta
band (%)was significantly higher in patients onperitoneal dialysis (PD), compared
with control group (51.5±12.3 vs 23.9±14.3, ∗P<0.001). Boxes represent
means; error bars indicate the 95% of CI (confidence interval). CKD=chronic
kidney disease, HC=healthy controls, HD=hemodialysis, KT=kidney trans-
plantation, PD=peritoneal dialysis, RelDelta= relative power of delta band.
Figure 3. Linear regression plot. 1,25-(OH)2D3 (ng/mL) vs RelDelta (%) in
overall population. Negative correlation was found between the 2 parameters
(r=0.820, P<0.001). 1,25-(OH)2D3=1,25-dihydroxyvitamin D3ng/mL,
RelDelta= relative power of delta band.
Lai et al. Medicine (2016) 95:48 www.md-journal.comcorrelation with Pa (paranoia) (r=0.407, P<0.001), D (r=
0.615, P<0.001), Pd (psychopathic deviate) (r=0.56, P<0.001)
scales, and with hypochondria (r=0.791, P<0.001) (Table 3).
Moreover, Hy scale showed a positive correlation with Factor I
(psychological functioning), Factor II (physical functioning), and
Factor IV (sleep/diet/free time) (r=0.079, P=0.008, r=
0.309, P=0.007, r=0.309 P=0.007, respectively) of SAT-P
and with TMT (r=0.241, P=0.037) and SDMT (r=0.298, P=
0.009) of NPZ5 score, as well as with creatinine, MDRD, serum
nitrogen, CRP, and iPTH (r=0.292, P=0.011; r=0.300, P=
0.009; r=0.244, P=0.035; r=0.352, P=0.002; r=0.295,
P=0.010, respectively) (Table 3). The scales Pa of MMPI-2
showed a significant correlation with creatinine, MDRD, serum
nitrogen, CRP, 1,25-(OH)2D3, iPTH, phosphorus (r=0.554,
P<0.001; r=0.374, P=0.001; r=0.381, P=0.001; r=0.318,
P=0.005; r=0.255, P=0.027; r=0.246, P=0.033; r=
0.301, P=0.009, respectively), such as the scale Pd (psychopathicFigure 2. EEG visual analysys classification according to the Parsons–Smith
grading. Grade 1: normal EEG, Grade 2: distinctive features of encephalopathy,
Grade 3: signs of severe encephalopathy. CKD=chronic kidney disease, HC=
healthy controls, HD=hemodialysis, KT=kidney transplantation, PD=perito-
neal dialysis.
5deviate) (r=0.402, P<0.001; r=0.532, P<0.001; r=0.488,
P<0.001; r=0.447, P<0.001; r=0.374, P<0.001; r=
0.331, P=0.004; r=0.283, P=0.014, respectively). The scale
Pd ofMMPI-2, showed also a significant correlation with RAVL,
DST, SDMT, and TMT tests, of NPZ5 score (r=0.271, P=
0.019; r=0.270, P=0.019; r=0.318, P=0.005; r=0.283, P=
0.014, respectively) (Table 3), while the TRT (negative treatment
indicators), an alternative scale ofMMPI-2, that indicate negative
attitudes of the subject towards health treatments, showed a
negative correlation with factor IV of SAT-P (r=327, P=
0.004), that indicate sleep/diet/free time and with SDMT
(90–120seconds) of NPZ5 (r=304, P=0.008; r=0.311,
P=0.007), that assesses attention, visual scanning, and informa-
tion processing speed (data not shown). Moreover, the subscale
D2 (psychomotor retardation) showed a positive correlation with
DST and SDMT (r=0.289, P=0.12; r=0.262, P=0.23,Figure 4. Linear regression plot. RelDelta (%) vs MDRD (mL/min/1.73m2) in
overall population. Negative correlation was found between the 2 parameters
(r=0.617, P<0.001). MDRD=Modification Diet of Renal disease, RelDelta=
relative power of delta band.
Figure 5. Linear regression plot. CRP (mg/L) vs RelDelta (%) in overall
population. Positive correlation was found between the 2 parameters (r=0.850,
P<0.001). CRP=C reactive protein, RelDelta= relative power of delta band.
Lai et al. Medicine (2016) 95:48 Medicinerespectively) of NPZ5. At last, all NPZ5 scores showed a
significant difference between the means of nephropathic patients
and the means of the HC (Fig. 7), and a positive correlation with
MDRD, serum nitrogen, CRP, ESV, iPTH, and 1,25-(OH)2D3
(Table 4).
Table 5 shows SAT-P analysis and significant difference
between CKD patients and HC. PD patients showed the highest
level of satisfaction, while both patients, on conservative therapy
and with KT, showed significant differences compared to HC in
more domains of the test (Table 5).
5. Discussion
The neurological, psychological, and cognitive complications
related to CKD, could contribute to the morbidity, and poor
quality of life of these patients, but the prevalence, the
pathogenesis, and the eventual therapy, remain currently
unknown. The neurologic complications are better detected by
neurophysiological techniques rather than through the neuro-
images[4]; in fact, the EEG is very sensitive to the action of
metabolic imbalances and toxic factors. In our study, the
quantitative analysis of EEG data, showed a significant
difference, between CKD patients and HC, of the relative and
absolute power of delta, theta, and Beta1 band (Table 2). Delta
waves are usually associated with the deep stage 3, of nonrapid
eye movement sleep, or in early developmental stages. Increase in
delta power has been associated with autonomic and metabolic
processes, suggesting that it may be involved in the integration of
cerebral activity with homeostatic processes; in fact, it was found
increased in metabolic diseases, intoxication, and uremic
encephalopathy. The theta rhythm is dominant in the infant,
and may represent emotional tensions, it should not be present in
physiological conditions, in the waking state in adulthood, but
may appear in general anesthesia and in some brain diseases, or in
general metabolic diseases, such as uremic encephalopathy. Beta
waves are dominant in the waking state, but also in alert state and
in rapid eyemovement sleep. Also the qualitative analysis of EEG,
showed some differences, with a more regular and stable EEG, on
conservative therapy and KT patients, respect to dialysis patients.
Therefore, renal replacement therapy, could not be able to
completely remove the possible substances involved in the6pathogenesis of neurological disorders, without difference
between PD and HD, as previously reported by Burn and Bates
in 1998.[4] However, also in conservative therapy patients, EEG
showed a lower percentage of Grade 2 and even Grade 3 on KT
patients, respect to HC (Fig. 2). Therefore, KT, certainly remains
the best therapeutic option, nevertheless, neurological distur-
bances could persist, even 3 years after transplant. Moreover, our
study showed, a positive correlation between the relative power
of delta band and reduced eGFR (Fig. 4), which could indicate an
initial alteration in patients with CKD stage 4 KDOQI, as
previously reported by Elias and Elias[7] and Kurella Tamura and
Wadley[8]. The mechanisms of central nervous system dysfunc-
tion in CKD aremultifactorial and only partially characterized; in
fact, it has long been exclusively attributed to the increase in the
serum concentration of urea, whereas the literature is considering
other possible pathogenic mechanisms. Several guanidino
compounds (GCs) could play an important role, indeed, 4
GCs (creatinine, guanidine, guanidinosuccinic acid, and meth-
ylguanidine), appeared to be highly increased in serum, brain,
and cerebrospinal fluid of patients with CKD, and all were shown
to be experimental convulsants in brain concentrations similar to
those found in uremic brain. De Deyn et al[22] have described
possible excitatory effects of uremic GCs on the central nervous
system by the activation of N-methyl-D-aspartate receptors by
guanidinosuccinic acid, and a concomitant inhibition of GABAA
receptors by uremic GCs. Furthermore, a multitude of potential
uremic toxins, including the nitric oxide synthase, modulating
GCs, a decreased brain energy demand, some free amino acid
changes, blood–brain barrier derangement and vascular disease,
have been implicated in neurologic complications of CKD.[23] In
addition to these mechanisms, some studies seem to indicate that
neuropsychological alterations, could be, at least in part, due to
inflammatory mechanisms, involving soluble and cellular
mediators.[24] Our study confirmed a significant difference,
between CKD patients and HC, in CRP and ESV values (Table 1)
and it also showed, a positive correlation between relative power
of delta band, and CRP (Fig. 5) and ESV, and between NPZ5
scores and CRP and ESV (Table 4). Moreover, many alterations
of the central nervous system in CKD, could be mediated by
secondary hyperparathyroidism,[25] indeed parathyroidectomy
of animals with CKD, prevented the increase in basal levels of
intracellular calcium, and disorders in neurotransmitter metabo-
lism.[26,27] In our study, we have found a significant difference,
between CKD patients and HC, in iPTH and 1,25-(OH)2D3
values (Table 1) and a negative correlation between 1,25-(OH)
2D3 and relative power of delta band (Fig. 3). A variety of studies
found an association between a low level of vitamin D and a high
depression score.[28,29] Vitamin D deficiency was also associated
with prominent changes in behavior and brain neurochemistry in
the adult mouse.[30] The brain has a VDR (vitamin D receptors)
and has the ability to produce vitamin D, which seems to have a
neuroprotective role, inducing remyelination by endogenous
progenitor cells.[31] Driessen et al[25] showed that patients with
depressive disorders and CKD, presented a higher level of iPTH
when compared with nondepressed subjects; thus, secondary
hyperparathyroidism could be related to depressive symptoms.
Anglin et al[32] have analyzed more than 30,000 individuals,
finding a clear correlation between vitamin D deficiency and a
higher rate of depression. Furthermore, Mozaffari-Khosravi
et al[33] showed that a dose of 300,000 IU of vitamin D has been
able to improve the state of depression in a statistically significant
way, as reported by a recent review of Hoffman et al.[34] In our
study, MMPI-2 analysis, showed a difference between CKD
Table 3
Bivariate correlation between EEG (relative power of delta and theta band), MMPI-2 scale, Sat P, NPZ5 and renal function, mineral
metabolism and inflammation markers.
MMPI-2 Hy Cy SC2 SC4 Fam DEP Gm Gf Pa Pd
Rel delta band r 0.150 0.276 0.007 0.029 0.002 0.043 0.230 0.048 0.057 0.175
P 0.200 0.016 0.951 0.804 0.985 0.711 0.092 0.435 0.625 0.134
Rel theta band r 0.277 0.029 0.302 0.226 0.248 0.239 0.346 0.244 0.009 0.092
P 0.016 0.804 0.008 0.051 0.032 0.039 0.002 0.035 0.936 0.433
Hy r 1.000 0.298 0.249 0.327 0.286 0.318 0.176 0.132 0.407 0.564
P — 0.009 0.031 0.004 0.013 0.005 0.102 0.383 <0.001 <0.001
Pa r 0.407 0.072 0.635 0.540 0.579 0.634 0.518 0.900 1.000 0.687
P <0.001 0.542 <0.001 <0.001 <0.001 <0.001 0.015 <0.001 — <0.001
Dep r 0.615 0.376 0.667 0.683 0.835 1.000 0.643 0.000 0.634 0.516
P <0.001 <0.001 <0.001 <0.001 <0.001 — <0.001 0.997 <0.001 <0.001
Pd r 0.564 0.113 0.491 0.541 0.456 0.516 0.229 0.049 0.687 1.000
P <0.001 0.334 <0.001 <0.001 <0.001 <0.001 0.104 0.376 <0.001 —
Hs r 0.791 0.111 0.141 0.182 0.275 0.294 0.163 0.161 0.366 0.431
P <0.001 0.343 0.229 0.118 0.017 0.010 0.164 0.159 <0.001 <0.001
Factor I r 0.079 0.223 0.078 0.282 0.206 0.207 0.230 0.048 0.030 0.023
P 0.008 0.055 0.504 0.014 0.076 0.075 0.092 0.435 0.801 0.846
Factor II r 0.309 0.097 0.008 0.125 0.041 0.099 0.021 0.858 0.057 0.017
P 0.007 0.408 0.945 0.286 0.725 0.396 0.084 0.475 0.625 0.886
Factor IV r 0.309 0.282 0.001 0.122 0.028 0.133 0.021 0.084 0.005 0.052
P 0.007 0.014 0.995 0.297 0.812 0.255 0.858 0.475 0.965 0.657
RAVL test r 0.180 0.263 0.031 0.071 0.039 0.101 0.301 0.103 0.036 0.271
P 0.122 0.022 0.791 0.546 0.740 0.387 0.009 0.379 0.758 0.019
TMT r 0.241 0.166 0.274 0.131 0.179 0.065 0.038 0.748 0.051 0.273
P 0.037 0.154 0.018 0.262 0.124 0.577 0.067 0.569 0.661 0.020
SDMT r 0.298 0.389 0.033 0.026 0.106 0.100 0.270 0.134 0.113 0.270
P 0.009 <0.001 0.780 0.826 0.365 0.393 0.019 0.251 0.336 0.019
DST r 0.157 0.051 0.097 0.036 0.020 0.026 0.052 0.655 0.139 0.318
P 0.178 0.665 0.406 0.759 0.862 0.826 0.220 0.057 0.235 0.005
Creatinine, mg/dL r 0.292 0.303 0.228 0.305 0.230 0.260 0.097 0.291 0.554 0.402
P 0.011 0.008 0.049 0.008 0.048 0.024 0.409 0.011 <0.001 <0.001
MDRD, mL/min r 0.300 0.272 0.228 0.282 0.153 0.218 0.084 0.287 0.374 0.532
P 0.009 0.018 0.049 0.014 0.191 0.060 0.473 0.013 <0.001 <0.001
Nitrogen, mg/dL r 0.244 0.215 0.317 0.306 0.206 0.160 0.083 0.291 0.381 0.488
P 0.035 0.065 0.006 0.008 0.076 0.171 0.477 0.011 <0.001 <0.001
CRP, mg/L r 0.352 0.212 0.187 0.262 0.121 0.177 0.067 0.250 0.318 0.447
P 0.002 0.068 0.108 0.023 0.302 0.129 0.569 0.030 0.005 <0.001
iPTH, pg/mL r 0.295 0.069 0.165 0.259 0.210 0.236 0.005 0.152 0.255 0.374
P 0.010 0.554 0.156 0.025 0.071 0.041 0.964 0.192 0.027 <0.001
1,25-(OH)2D3, ng/mL r 0.128 0.130 0.261 0.323 0.039 0.250 0.012 0.092 0.246 0.331
P 0.275 0.265 0.023 0.005 0.740 0.030 0.919 0.432 0.033 0.004
P, mg/dL r 0.156 0.036 0.129 0.191 0.160 0.177 0.061 0.181 0.301 0.283
P 0.180 0.757 0.271 0.101 0.172 0.129 0.603 0.121 0.009 0.014
MMPI-2=Minnesota multiphasic personality inventory, Scale of MMPI2: Hy=hysteria, Cy=cynicism, SC2= emotional alienation, SC4=depressive tendency and apathy, Fam= family problems, DEP=
depression, Gm=gender male; the perception of sexual role, Gf=gender female, Pa=paranoia, Pd=psychopathic deviation, scale of SAT-P (satisfaction profile test): Factor I, psychological functioning; Factor II,
physical functioning; Factor IV, sleep/diet/free time; domain of NPZ5 (neuropsychological test): RAVL=Rey auditory verbal learning test, TMT= trail-making test, SDMT= symbol digit modalities test, DST=digit
eliminare spain test, DST=digit span test, MDRD=modification diet of renal disease, CRP=C-reactive protein, iPTH= intact parathormone, 1,25-(OH)2D3=1-25-dihydroxyvitamin D3, P=phosphorus.
Bold highlights the statistically significant values.
Lai et al. Medicine (2016) 95:48 www.md-journal.compatients and HC, in all baseline clinical scale D (depression),
already present in conservative therapy and not completely
disappear in KT patients, even if, only HD and PD patients,
showed a significant difference respect to HC (Fig. 6). Lack of
vitamin D has a high prevalence in patients with renal disease in
which the traditional causes of deficits (lack of sunlight exposure,
reduced dietary intake), combine with those of the CKD (reduced
synthesis in the skin, urinary loss of vitamin D, and vitamin D
binding protein (DBP), loss of renal mass and function with
reduced activity of 1a-hydroxylase, increased FGF-23). The
decreased activation of vitamin D is reflected in proportional
increases in circulating levels of iPTH, due in part to the decrease7in intestinal absorption of calcium, and thus to the reduction of
Ca ionized circulating, in part to the absence of the negative
feedback directly exercised by vitamin D on the VDR on
parathyroid.[4,35] Others potential risk factors, could be the
anemia, as reported in other studies[36] and confirmed in our
study, with a significant difference of hemoglobin value (Table 1),
and the hyperuricemia (Table 1), possible endothelial dysfunction
index.[37] These alterations, could, at least partially, contribute to
explain the early neuropsychological and cognitive decline in
CKD, still poorly known.[38] In our study, theMMPI-2 scales, Hy
and Pa, are significantly correlated with creatinine, MDRD,
serum nitrogen, CRP, 1,25-(OH)2D3, iPTH, phosphorus;
Figure 6. Bar charts with error bars. The mean value of clinical Scale D (points)
was significantly higher in HD and PD patients compared with HC (71.4±15.7,
73.9±11.0 vs 53.7±5.4; P<0.001, P<0.001, respectively). Boxes represent
means; error bars indicate the 95% of CI. CI=confidence interval, CKD=
chronic kidney disease, D=depression, HC=healthy controls, HD=hemo-
dialysis, KT=kidney transplantation, PD=peritoneal dialysis.
Lai et al. Medicine (2016) 95:48 Medicinemoreover Hy and cyn are correlated with higher relative power of
theta and delta band (Table 3). Moreover, Pd scale showed a
significant correlation with Pa, Hy, depression scales, and all tests
of NPZ5 score, but a negative correlation with creatinine, serum
nitrogen, CRP, iPTH, and phosphorus, and a positive correlation
with MDRD, 1,25-(OH)2D3, indicating a low Pd in CKD. Pd
indicates the lack of control on emotional responses and the
ability to internalize the social rules and low value, could be
overly conventional and conforming, passive, and noncompeti-
tive. The cyn scale of MMPI-2, suggests a hostile and suspicious
personality. The Hy scale of MMPI2 indicates a tendency to
somatize some emotions and psychological discomforts with
anxiety, tension, and depression. In our study, Hy is associated
with Pa, which may lead to poor compliance, to difficulties in
communicating emotional problems and in establishing a
relationship with the therapists, in addition to depression with
unhappy, feeling weak, fatigued, and lacking energy. Moreover,Figure 7. Bar charts with error bars. NPZ5 (points) test results in nephropathic
indicate the 95% confidence interval. DST=digit span test, GPT: DH=Grooved Peg
hand, HC=healthy controls, NP=nephropathic patients, NPZ5=neuropsychologi
digit modalities test, TMT= trail making test.
8Hy and Cyn scales are associated with Factor I (psychological
functioning), Factor II (physical functioning), and Factor IV
(sleep/diet/free time) (Table 3) of Sat P-test, showing a
considerable psychological distress even in activities of daily
living, and with several tests of NPZ5 score, that indicate
cognitive disorders of attention, memory, motor, and manual
coordination. Moreover, all NPZ5 scores showed a statistically
significant difference between the means of nephropathic patients
and the means of the HC (Fig. 7), and a positive correlation with
MDRD, serum nitrogen, CRP, iPTH, and 1,25-(OH)2D3
(Table 4) showing a possible and early, cognitive deficit in
CKD patients on conservative therapy, and a noncomplete
recovery in KT patients, also after 3 years from transplantation,
associated with psychological disorders, that could jeopardize the
quality of family, work, and social life.[39] The start of dialysis is
an important change in a person’s life and determine stress for the
permanently and continuously commitment and the many
physical difficulties related to treatment, as well as the discomfort
caused by dietary and fluid intake restrictions.[40] These aspects
not only affect the personal habits but also the social and family
relationships, modifying and/or resizing the patient’s role in the
family and at work. The main causes of psychological distress in
CKD patients could be, the fear of death, but especially the
condition of dependence from healthcare, dialysis machine,
transplanted organ and/or family, which could be associated with
anxious and/or depression disorders. In the past, treating the
psychological, relational, and behavioral aspects of dialysis
patients was considered “secondary” to the need to keep the
patient alive. Currently, dialysis patients have an important
alternative to resignation, in fact, through multidisciplinary
interventions (nephrological, neurological, and psychological), is
possible reach advanced levels of adaptation, maintain good
compliance, with effective control of fluid intake and of weight
gain interdialytic, promoting significant improvements in the
quality of life and survival, enabling a significant reduction in the
healthcare costs worldwide.[39,40]5.1. Limitations of the study
This study is a pivotal study, conducted in relatively small cohort
of CKD patients; therefore, a larger population is requested to
confirm our results. Also, all patients were on therapies withpatients compared with healthy controls. Boxes represent means; error bars
board Test dominant hand, GPT: NDH=Grooved Pegboard Test nondominant
c z score for 5 tests, RAVL=Rey Auditory Verbal Learning test, SDMT=symbol
Table 4
Bivariate correlation between NPZ5 test score and others variables in overall population.
Creatinine, mg/dL MDRD, mL/min/1.72m2 Serum nitrogen, mg/dL CRP, mg/mL ESV, mm/h iPTH, pg/mL 1,25-(OH)2D3, ng/mL
RAVL: List A
r 0.549 0.547 0.527 0.467 0.292 0.383 0.465
P <0.001 <0.001 <0.001 <0.001 0.011 0.001 <0.001
RAVL: List B
r 0.409 0.407 0.428 0.408 0.337 0.320 0.365
P <0.001 <0.001 <0.001 <0.001 0.003 0.005 0.001
TMT: Parts A, s
r 0.134 0.109 0.237 0.339 0.199 0.364 0.464
P 0.252 0.350 0.040 0.003 0.086 0.001 <0.001
TMT: Parts B, s
r 0.227 0.216 0.244 0.331 0.108 0.315 0.244
P 0.050 0.062 0.035 0.004 0.358 0.006 0.035
DST: forward
r 0.130 0.161 0.210 0.151 0.133 0.324 0.290
P 0.265 0.166 0.070 0.195 0.254 0.005 0.012
DST: backward
r 0.388 0.408 0.442 0.281 0.321 0.499 0.432
P 0.001 <0.001 <0.001 0.015 0.005 <0.001 <0.001
SDMT: 90, s
r 0.444 0.456 0.384 0.366 0.290 0.311 0.258
P <0.001 <0.001 0.001 0.001 0.012 0.007 0.026
SDMT: 120, s
r 0.520 0.514 0.460 0.461 0.341 0.356 0.319
P <0.001 <0.001 <0.001 <0.001 0.003 0.002 0.005
GPT: DH, s
r 0.172 0.337 0.187 0.262 0.116 0.177 0.212
P 0.141 0.003 0.108 0.023 0.321 0.129 0.068
GPT: NDH, s
r 0.076 0.156 0.049 0.098 0.061 0.045 0.204
P 0.515 0.181 0.679 0.402 0.605 0.699 0.080
1,25-(OH)2D3=1,25-dihydroxyvitamin D3 (ng/mL), CRP=C reactive protein, DST=digit span test, ESV= erythrocyte sedimentation velocity, GPT: DH=Grooved Pegboard Test dominant hand, GPT: NDH=
Grooved Pegboard Test nondominant hand, iPTH= intact parathyroid hormone, MDRD=Modification of Diet in Renal Disease, NPZ5=neuropsychologic z score for 5 tests, RAVL=Rey Auditory Verbal Learning
test, SDMT= symbol digit modalities test, sec= seconds, TMT= trail making test.
Bold highlights the statistically significant values.
Lai et al. Medicine (2016) 95:48 www.md-journal.comcalcium, calcitriol, and phosphate binders and their treatments
could have confounded the results. It seems that future large-scale
studies are needed to clarify these differences.
6. Conclusions
The results of our study underscore the importance to employ
simple and noninvasive instruments, as EEG, and cognitive–-Table 5
Satisfaction profile analysis and comparison with healthy controls.
CKD (n=22)
Factor I 58.31±8.09 5
HC (n=25): 69.42±22.25 P=0.0031
Factor II 40.53±10.58 3
HC (n=25): 59.14±12.36 P<0.001
Factor III 54.52±22.3 4
HC (n=25): 63.70±22.77 P=0.17
Factor IV 56.41±21.85 5
HC (n=25): 62.60±16.98 P=0.28
Factor V 77.33±8.53 6
HC (n=25): 75.19±13.44 P=0.52
Data are show as mean± standard deviation.
Domains of satisfaction profile test—Factor I: psychological functioning, Factor II: physical functioning,
CKD= chronic kidney disease, HC=healthy controls, HD=hemodialysis, KT= kidney transplant, PD=p
Bold highlights the statistically significant values.
9psychological tests, for early identification of patients at risk of
developing neurological, psychological, and cognitive disorders.
Could be important, also, carry out careful and constant
monitoring of renal risk factors, probably involved in neuropsy-
chological complications (inflammation, disorders of mineral
metabolism, electrolyte disorders, etc.). Early identification and
adequate therapy of neuropsychological, and cognitive disorders,HD (n=15) PD (n=16) KT (n=21)
7.02±8.10 63.97±8.91 58.03±17.43
P=0.045 P=0.35 P=0.06
9.08±19.34 56.81±19.56 35.41±20.74
P<0.001 P=0.64 P<0.001
3.00±27.81 61.94±11.36 49.69±22.07
P=0.014 P=0.77 P=0.040
3.67±15.20 61.96±11.86 53.81±16.23
P=0.10 P=0.89 P=0.08
8.62±18.20 67.21±12.69 59.43±17.18
P=0.19 P=0.06 P<0.001
Factor III: work, Factor IV: sleep/diet/free time, Factor V: social functioning.
eritoneal dialysis
[19] Meuti V,Marini I, Grillo A, et al.MMPI-2: cluster analysis of personality
Lai et al. Medicine (2016) 95:48 Medicinemight enable a better quality of life and a major compliance with
a probable reduction in the healthcare costs. For this purpose a
multidisciplinary interventions could be recommendable.References
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